Sensus Healthcare, Inc. (SRTS)

Over the past six months, Sensus Healthcare's stock price has experienced a significant decline. Key events impacting the stock include the Q3 2025 earnings report where the company reported a loss of ($0.06) earnings per share, topping the consensus estimate of ($0.12), and revenue was reported at $6.9M, beating estimates by $0.59M. The Q2 2025 earnings report showed a loss of ($0.06) earnings per share. Q4 2024 showed a significant miss in profitability despite a 4% year-over-year sales growth. Sensus Healthcare appointed Larry Biscotti and Eric Sachetta to its Board of Directors, and Michael Sardano's role was expanded. Sensus Healthcare insiders have bought more of their company's stock than they have sold in the past three months.

Management has indicated that Q1 is historically a weaker quarter for sales due to seasonal factors, suggesting some level of demand seasonality for Sensus Healthcare's products and services.

Sensus Healthcare, Inc. (SRTS) is a medical device company specializing in the development, manufacture, and commercialization of superficial radiation therapy (SRT) systems. The company operates within the Healthcare sector, specifically in the Medical Devices and Healthcare Equipment & Supplies industry. Sensus Healthcare's core technology utilizes low-energy X-rays to provide non-invasive treatment alternatives for various dermatological and oncological conditions. Its major products include SRT-100™, SRT-100 Vision™, SRT-100 Plus™, Sentinel™ service program, and a Transdermal Infusion system. The company also distributes laser devices for various applications.

Sensus Healthcare, Inc. markets its products primarily to private dermatology practices and radiation oncologists in both private and hospital settings worldwide. The company's revenue is generated predominantly from customers in the United States.

Sensus Healthcare's brand reputation in the past year appears to be generally stable with some positive recognition and ongoing analyst coverage. Sensus Healthcare was named to TIME's America's Growth Leaders of 2026, and CMS established coding validating Sensus SRT for treating non-melanoma skin cancer. The company has a consensus rating of "Hold" from MarketBeat, and analysts forecast a potential upside of 73.5% from its current price. The company demonstrated significant growth in shipping operations and reported strong financial performance for FY2024. Investment risks are related to the commercial success of SRT and TransDermalInfusion systems, potential reimbursement issues, increased competition, and the risk of dilution impacting shareholder value.

Individual investors hold the largest share in Sensus Healthcare, Inc., with 47% ownership, while institutions own 32% of the company. Major institutional owners include Vanguard Group Inc., Pacific Ridge Capital Partners, LLC, Dimensional Fund Advisors Lp, BlackRock, Inc., Perritt Capital Management Inc., Renaissance Technologies Llc, and Acadian Asset Management Llc. Key individual owners include Joseph Sardano (CEO), Edwin Solot, and Stephen Cohen.